-
Product Insights
NewNet Present Value Model: Inhibikase Therapeutics Inc’s Risvodetinib
Empower your strategies with our Net Present Value Model: Inhibikase Therapeutics Inc's Risvodetinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Constipation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Constipation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Constipation Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Dysphagia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Dysphagia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Dysphagia Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Parkinson's Disease Drug Details: Risvodetinib succinate (Ikt-148009) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afamitresgene Autoleucel in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afamitresgene Autoleucel in Squamous Non-Small Cell Lung Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Progressive Multifocal Leukoencephalopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2023’, provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Polyomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Polyomavirus Infections - Drugs In Development, 2023’, provides an overview of the Polyomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polyomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lewy Body Dementia – Drugs In Development, 2023
Global Markets Direct’s, ‘Lewy Body Dementia - Drugs In Development, 2023’, provides an overview of the Lewy Body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2023’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...